Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial

Citation
Heerspink HJL, Stefansson BV, Chertow GM, et al. Nephrol Dial Transplant 2020;35:274–82.